<DOC>
	<DOCNO>NCT00139620</DOCNO>
	<brief_summary>This multicenter , open-label , 2-arm study compare erlotinib exposure cancer patient adequate hepatic function versus cancer patient moderate hepatic impairment . All patient receive single 150 mg dose erlotinib Day 1 follow 96 hour plasma sample PK protein bind study . Patients may enter maintenance phase study continue receive erlotinib disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Pharmacokinetic Study Erlotinib Cancer Patients With Advanced Solid Tumors , With Adequate Moderately Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm advanced solid tumor ( measurable nonmeasurable ) potentially responsive erlotinib effective therapy available , Cohort 1 : Adequate hepatic function : bilirubin &lt; = ULN , ALT ( SGPT ) AST ( SGOT ) &lt; = 1.5 x ULN Cohort 2 : Moderate hepatic function : 79 assess ChildPugh System , ECOG Performance Status 02 Life expectancy &gt; = 12 week , Prior radiation permit provide 4 week ( 2 week palliative radiation ) elapse patient recovered acute toxic effect radiotherapy , Prior chemotherapy permit provide 4 week elapse patient recovered acute toxic effect chemotherapy , Adequate hematopoietic renal function : ANC &gt; = 1.5 x 10^9/L , platelet &gt; = 75 x 10^9/L , creatinine &lt; = 1.5 x ULN , Use tobacco nicotinecontaining product within 4 week Day 1 study , Use CYP3A4 inhibitor inducer within 14 day prior Day 1 Day 5 , Use warfarinderivative anticoagulant within 14 day prior Day 1 Day 5 , Encephalopathy &gt; = grade 2 , Significant history cardiac disease unless wellcontrolled , Active uncontrolled infection serious illness medical condition could interfere patient 's ongoing participation , Concurrent anticancer therapy investigational agent within 4 week Day 1 study , Symptomatic brain metastasis stable , require steroid , potentially lifethreatening , require radiation within last 4 week , Gastrointestinal abnormality , include inability take oral medication , requirement IV alimentation , active peptic ulcer prior surgical procedure affect absorption .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>advanced cancer , solid tumor</keyword>
</DOC>